How Does the Experimental ‘Vaccine’ for Celiac Disease Work?


An experimental "vaccine" for celiac disease is set to be tested in a new clinical trial to see if the treatment can protect patients with the condition from the effects of eating gluten — or, in other words, allow those patients to eat gluten safely.

The treatment, called Nexvax2, made by the biotech company ImmusanT, Inc., is a type of immunotherapy that aims to "reprogram" the immune system to be tolerant of gluten, the researchers said.

Celiac disease is a condition in which people's immune systems react abnormally to gluten — a protein found in wheat, rye and barely — and this reaction damages the lining of the small intestine. The condition affects about 1 out of every 100 people in the United States. [11 Ways Processed Food Is Different from Real Food]

Currently, the only way to manage celiac disease is for patients to avoid foods containing gluten for the rest of their lives. But even with the rise in popularity of gluten-free foods, such diets can still be difficult to follow, and patients may be inadvertently exposed to the protein. "Even the most diligent patients can suffer the adverse effects of accidental exposure," study researcher Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, said in an Oct. 30 statement.

Nexvax2 works in a way that's similar to allergy shots. The treatment — which consists of twice-weekly injections administered over a 16-week period — is made up of molecules called peptides, which elicit an immune response in patients with celiac disease. In theory, exposure to the peptides over time could help reprogram immune cells called T cells to become tolerant of gluten and no longer trigger an immune response, according to ImmusanT. This could allow patients with celiac disease to eat a diet that includes gluten.

The vaccine is intended for celiac disease patients who carry an immune system gene called HLA-DQ2.5 that is found in about 90 percent of celiac disease patients, the company said.

In an earlier trial of Nexvax2 in a small group of people, researchers showed the vaccine was safe and well-tolerated among patients with celiac disease. The new study, which will include around 150 patients, aims to further test the safety, as well as effectiveness of the treatment.

"This [new] trial is important in establishing clinical proof-of-concept for a treatment that would provide benefit beyond that of the gluten-free diet," Tye-Din said. (Proof-of-concept means that the trial would show that the treatment works as intended.)

The company is currently recruiting patients in Australia, New Zealand and the United States to participant in the trial, according to

Originally published on Live Science.